Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial. J of Skin 2020, 4 (6), s102. https://doi.org/10.25251/skin.4.supp.102.